DSGN(DSGN)
DSGN
ANALYST COVERAGE7 analysts
BUY
▲ +63.6%upside to target
L $14.00
Med $17.50consensus
H $21.00PRICE
Prev Close
14.37
Open
15.94
Day Range10.00 – 16.95
10.00
16.95
52W Range3.31 – 17.25
3.31
17.25
53% of range
VOLUME & SIZE
Avg Volume
397.9K
FUNDAMENTALS
P/E Ratio
-8.9x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.77
High vol
TECHNICAL
RSI (14)
60
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 105 days
Aug 31
Key MetricsTTM
Market Cap$668.29M
Revenue TTM$0.00
Net Income TTM-$69.71M
Free Cash Flow-$54.12M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-33.1%
Return on Assets-30.3%
Debt / Equity0.01
Current Ratio22.28
EPS TTM$-1.13
DSGN News
About
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.
Industry
Research and Development in Biotechnology
Website
Aseem Z. AnsariCo-Founder & Scientific Advisor
Chengzhi ZhangChief Chemist
Chris StorgardChief Medical Officer
Sean JeffriesChief Operating Officer
Tadimeti S. RaoChief Scientific Officer
Doane ChilcoatChief Technology Officer
Jim KerrChief of Manufacturing & Product Development
Mustapha ParekhGeneral Counsel
Pratik ShahCo-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive Chairperson
Julie D. BurgessChief Accounting Officer